Bychkovsky, Brittany
Laws, Alison
Katlin, Fisher
Hans, Marybeth
Knust Graichen, Mary
Pace, Lydia E.
Scheib, Rochelle
Garber, Judy E.
King, Tari A. http://orcid.org/0000-0003-3602-2351
Funding for this research was provided by:
Susan G. Komen
Article History
Received: 1 February 2022
Accepted: 17 March 2022
First Online: 4 April 2022
Declarations
:
: J.E.G. reports institutional research funding from Myriad Genetics, Ambry Genetics, and Invitae Genetics; consulting for Helix Genetics (compensation) and Earli (no compensation); leading two clinical trials for Astra-Zeneca; serving on the scientific advisory board of Konica Minolta (no compensation); conducting a sponsored lecture for Clinical Care Options, LLC; Editorial Services publications, President, Fellows of the AACR Academy, and member, Foundation Board of the American Association for Cancer Research; co-scientific director, Breast Cancer Research Foundation; board of directors, Facing Our Risk of Cancer Empowered; spousal consulting fees from Novartis Oncology, GTx Pharmaceuticals, Aleta BioTherapeutics and H3 Biomedicine, Inc.; a spousal advisory board membership at Oric Pharmaceuticals; and spousal scientific advisory board memberships at Kronos Bio, Susan G. Komen for the Cure, James P. Wilmot Foundation, Inc., Diane Helis Henry Medical Research Foundation, Adrienne Helis Melvin Medical Research Foundation, and Global Biological Standards Institute. T.K. reports speakers honoraria and advisory board for Exact Sciences (formerly Genomic Health); Faculty – PrecisCa Cancer information service; and serving on the Global advisory board for Besins Healthcare . All remaining authors have declared no conflict of interest.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the IRB of Brigham and Women’s Hospital.
: The study was approved by the Brigham and Women’s Institutional Review Board as a low-risk study and approved with a waiver of consent.
Free to read: This content has been made available to all.